Inclusion of data generated through morphologically-directed Raman spectroscopy (MDRS), can support a cost-effective and efficient approach to generic nasal product development.

Challenges to achieving generic nasal product development

Companies bringing generic, off-patent nasal medicines to market are required to conduct potentially costly bioequivalence studies to ensure the safety and efficacy of their products. For the US market, where a weight of evidence approach has historically been required, this has often involved clinical endpoint (PD) studies, which are both expensive and time-consuming.

It is even more difficult to gain approval without PD data for locally acting nasal sprays as it is often impossible to accurately conduct PK studies, placing more emphasis on the in-vitro data generated.

However, advances in analytical technology has meant that the U.S. Food & Drug Administration (FDA) Centre for Drug Evaluation and Research (CDER) were able to grant approval to Apotex’s abbreviated new drug application (ANDA) for Mometasone Furoate nasal spray without PD data. The article in reference 1 describes how the approval hinged on Apotex’s use of morphologically directed Raman spectroscopy (MDRS) data as part of the submission. This test was included along with the in-vitro BE tests set out in the guidance for this product and together, meant that a strong enough package of data was presented to satisfy the authorities that no clinical endpoint study should be performed.

Meeting regulatory requirements through cost-effective and efficient approaches, such as the inclusion of MDRS data, is of huge interest to generics developers and should support the development and approval of more generic nasal products in the future.

Intertek’s inhalation development expertise

Intertek’s integrated formulation and analytical team for inhalation and nasal medicines apply their 20 years of experience to formulation development, method development and validation, analytical testing, solubility screening, drug-excipient compatibility, stability testing and device selection support.

Through our Total Quality Assurance expertise, we consistently deliver with precision, pace and passion, enabling you to overcome challenges in respiratory development.

FOR MORE INFORMATION

+44 1763 261 648

inhalation@intertek.com

intertek.com/inhalation-nasal

1 FDA Embraces Emerging Technology for Bioequivalence Evaluation of Locally Acting Nasal Sprays; Li Ling, June 2016